GSK forms partnership with Vodafone to help increase childhood vaccination in Mozambique
10 December 2012 | By GlaxoSmithKline
Partnership aims to create sustainable and scalable model to be replicated across Africa...
List view / Grid view
News
Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin
10 December 2012 | By Boehringer Ingelheim
Results from a new post-hoc analysis...
Amgen to acquire deCODE Genetics
10 December 2012 | By Amgen
Amgen and deCODE Genetics announced that the companies have entered into a definitive agreement under which Amgen will acquire deCODE Genetics...
Boehringer Ingelheim to initiate Phase III study in leukaemia with its compound volasertib* based on positive Phase II results
10 December 2012 | By Boehringer Ingelheim
New positive Phase II results...
Gilead Board approves two-for-one stock split
10 December 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that its Board of Directors has approved a two-for-one stock split...
Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
Elotuzumab progression-free survival data from Phase 2 study of patients with previously-treated multiple myeloma presented at 54th ASH Annual Meeting
9 December 2012 | By Bristol-Myers Squibb Company
Results from Phase 2 open-label study...
Phase II Trial of Sanofi JAK2 inhibitor in myelofibrosis met primary endpoint
9 December 2012 | By Sanofi
New data presented at American Society of Hematology Annual Meeting show activity against disease and symptom alleviation...
Roche reports positive studies of MabThera given by subcutaneous injection
8 December 2012 | By Roche
Roche announced results from two studies...
Roche’s Perjeta significantly extends survival in people with HER2-positive metastatic breast cancer
8 December 2012 | By Roche
Roche announced updated survival results from the Phase III CLEOPATRA study...
ELIQUIS® (apixaban) demonstrated superiority in reducing a composite of recurrent venous thromboembolism and all-cause death without increasing the rate of major bleeding versus placebo during one year of extended treatment
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
Abbott announces effectiveness of AbbVie Form 10 Registration Statement
7 December 2012 | By Abbott
Abbott expects to complete separation of AbbVie on Jan. 1, 2013...
Save hours and expand laboratory throughput with the new ANATEL Autosampler
7 December 2012 | By Hach Company
Hach Company is pleased to announce the release of the ASX 7200 Autosampler...
Cisbio Bioassays and BellBrook Labs enter into distribution agreement for Transcreener® EPIGEN Methyltransferase assay
6 December 2012 | By Ballou PR
Distribution agreement...
Janssen submits applications requesting approval of STELARA® in U.S. and Europe for treatment of active Psoriatic Arthritis
6 December 2012 | By Johnson & Johnson
"We are pleased to present applications..."
